[
  {
    "ts": null,
    "headline": "4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street",
    "summary": "As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year, thanks to excellent clinical or regulatory progress.  Read on to learn more about four biotechs with price targets that imply significant upsides (based on prices as of Apr. 3) of between 50% and 543% in the next year.  Of the pure-play gene editing specialists on the market, CRISPR Therapeutics (NASDAQ: CRSP) is one of the more prominent.",
    "url": "https://finnhub.io/api/news?id=35e6123141288436a25ef4193f12a4c642c0c601f45deb0dfa106243770dd1e5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744027740,
      "headline": "4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street",
      "id": 133738996,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year, thanks to excellent clinical or regulatory progress.  Read on to learn more about four biotechs with price targets that imply significant upsides (based on prices as of Apr. 3) of between 50% and 543% in the next year.  Of the pure-play gene editing specialists on the market, CRISPR Therapeutics (NASDAQ: CRSP) is one of the more prominent.",
      "url": "https://finnhub.io/api/news?id=35e6123141288436a25ef4193f12a4c642c0c601f45deb0dfa106243770dd1e5"
    }
  },
  {
    "ts": null,
    "headline": "Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)",
    "summary": "Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Incyte (NASDAQ:INCY) and the best and worst performers in the immuno-oncology industry.",
    "url": "https://finnhub.io/api/news?id=aa55500cedceeea1397051a5084f860bb969b887e0e37091a573a9d0f24b0721",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744016487,
      "headline": "Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)",
      "id": 133738998,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Incyte (NASDAQ:INCY) and the best and worst performers in the immuno-oncology industry.",
      "url": "https://finnhub.io/api/news?id=aa55500cedceeea1397051a5084f860bb969b887e0e37091a573a9d0f24b0721"
    }
  }
]